Business
Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop Artificial Intelligence (AI) software with blue light cystoscopy (BLC®). Initial testing shows promising performance results.
About this update from Photocure Asa
[{"type":"text","content":"OSLO, Norway, Oct. 15, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop Artificial Intelligence (AI) software with blue light cystoscopy (BLC®). Initial testing shows promising performance results.","length":325,"tagName":"p"},{"type":"text","content":"Photocure and ISC have signed a development agreement on AI software and BLC for the detection of bladder tumors. Photocure is a pioneer in the bladder cancer diagnostics market with its Hexvix®/Cysview® products, supported by robust clinical evidence and treatment guidelines. ISC, based in the U.S., is a subsidiary of Claritas HealthTech Limited, based in the UK. Claritas and its affiliates, together with ISC, develop leading endoscopy solutions that ISC commercializes.","length":475,"tagName":"p"},{"type":"text","content":"In the current development phase, Photocure and ISC are collaborating to develop an AI software which can support the physician in real-time during blue light cystoscopy, improving early-stage bladder cancer detection, diagnosis, and resection completeness. The initial testing results were based on approximately 200 blue light procedures with more than 80,000 images. These results support the benefits of AI enabled blue light cystoscopy by detecting high risk cancerous lesions earlier in the patient pathway and more accurately.","length":533,"tagName":"p"},{"type":"text","content":"Photocure will support the development collaboration through an initial clinical study, with the aim to collect blue light videos and images from bladder cancer patients, at multiple sites in the U.S. and Europe, to train the blue light AI software. Details of the study (ENAiBLE) can be found on clinicaltrials.gov (https://clinicaltrials.gov/study/NCT07144319).","length":363,"tagName":"p"},{"type":"text","content":"Upon completion of the development, Photocure and ISC intend to pursue FDA clearance for the AI software compatible with any blue light cystoscope system. Regulatory clearances will be pursued in parallel across Europe and other markets. The next milestone would be the beta-version of the new Blue light AI detection software within 12-18 months, ahead of regulatory review.","length":375,"tagName":"p"},{"type":"text","content":"Based on the terms ...